EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0380-13	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-13)	2020-04-23
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0380-68	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0380-68)	2020-04-23
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0385-77	60 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-77)	2020-04-23
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0385-86	180 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0385-86)	2020-04-23
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0390-13	90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13)	2020-04-23
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0390-71	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71)	2020-04-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the key suppliers and patent landscape for the combination drug product containing empagliflozin, linagliptin, and metformin hydrochloride. The focus is on active pharmaceutical ingredient (API) manufacturing and relevant intellectual property that could impact market entry and competition.

What is the Combination Drug Product?

The combination drug product is a fixed-dose formulation containing three active pharmaceutical ingredients:

Empagliflozin: A sodium-glucose cotransporter-2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus [1].
Linagliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus [2].
Metformin Hydrochloride: A biguanide antihyperglycemic agent used as a first-line treatment for type 2 diabetes [3].

These components are often prescribed together to achieve synergistic glycemic control. The fixed-dose combination offers convenience for patients.

Who are the Primary API Suppliers for These Components?

Identifying specific, publicly disclosed API suppliers for the exact combination product is challenging due to proprietary supply chain agreements. However, analysis of patent literature, regulatory filings, and industry databases reveals key manufacturers and their capabilities for each individual API. These companies are potential suppliers to formulators of the combination product.

Empagliflozin API Suppliers

The primary innovator of empagliflozin is Boehringer Ingelheim. Manufacturing often involves complex multi-step synthesis.

Boehringer Ingelheim: As the originator, Boehringer Ingelheim is a primary manufacturer. Their internal manufacturing capabilities are extensive.
Generic API Manufacturers: Post-patent expiry or for regions where patents are weaker, specialized API manufacturers develop generic empagliflozin. These often operate in India and China. Examples of companies involved in the synthesis of SGLT2 inhibitors, including empagliflozin intermediates or API, include:
- Divi's Laboratories: Known for complex multi-step synthesis and large-scale production of APIs.
- Laurus Labs: Active in the development and manufacturing of APIs for various therapeutic areas, including diabetes.
- Sun Pharmaceutical Industries: A major generic pharmaceutical company with significant API manufacturing operations.
- Zydus Lifesciences: Involved in the development and production of APIs for chronic diseases.

Linagliptin API Suppliers

The originator of linagliptin is Boehringer Ingelheim. Similar to empagliflozin, the synthesis is a multi-step chemical process.

Boehringer Ingelheim: As the innovator, they maintain significant manufacturing capacity for linagliptin.
Generic API Manufacturers: The generic market for DPP-4 inhibitors is competitive. Key players in generic API manufacturing are likely to produce linagliptin.
- Aarti Industries: Has demonstrated capabilities in complex heterocyclic chemistry relevant to DPP-4 inhibitors.
- Granules India: A significant supplier of APIs for various therapeutic classes, including diabetes.
- Natco Pharma: Known for developing and manufacturing complex generics, including APIs.
- Hikma Pharmaceuticals: While also a finished dosage form manufacturer, they have API capabilities and can be a source for various generics.

Metformin Hydrochloride API Suppliers

Metformin hydrochloride is a high-volume, established generic drug. Its synthesis is well-understood and performed by a broad range of API manufacturers globally.

Wavelengths of Manufacturers: Due to its widespread use and long history, metformin HCl API is produced by a vast number of companies. Major generic API producing countries, particularly India and China, are dominant.
Prominent Manufacturers (examples):
- Shilpa Medicare: A significant manufacturer of metformin HCl with strong regulatory compliance.
- IPCA Laboratories: A large Indian pharmaceutical company with substantial API production.
- Torrent Pharmaceuticals: Another major Indian player in generic API manufacturing.
- Taiyo Chemical (Japan): Known for high-quality pharmaceutical ingredients.
- Zhejiang Huahai Pharmaceutical (China): A major global supplier of APIs.

Table 1: Potential API Suppliers and Associated Therapeutic Areas

API	Innovator	Potential Generic API Manufacturers (Examples)	Key Capabilities/Notes
Empagliflozin	Boehringer Ingelheim	Divi's Laboratories, Laurus Labs, Sun Pharmaceutical Industries, Zydus Lifesciences	Complex multi-step synthesis, SGLT2 inhibitor class
Linagliptin	Boehringer Ingelheim	Aarti Industries, Granules India, Natco Pharma, Hikma Pharmaceuticals	Heterocyclic chemistry, DPP-4 inhibitor class
Metformin HCl	Various	Shilpa Medicare, IPCA Laboratories, Torrent Pharmaceuticals, Taiyo Chemical, Zhejiang Huahai Pharmaceutical	High-volume production, established synthesis, broad global manufacturing base

Note: This list is not exhaustive and represents companies known for API manufacturing within these therapeutic classes. Actual supply chains are subject to proprietary agreements and market dynamics.

What is the Patent Landscape for These APIs and Their Combinations?

The patent landscape for empagliflozin and linagliptin is dominated by the originator, Boehringer Ingelheim, with a strong portfolio of composition of matter, formulation, and use patents. Metformin hydrochloride, being a very old drug, is largely off-patent for its basic composition and manufacturing.

Empagliflozin Patents

Composition of Matter: The primary patents for empagliflozin have expired or are nearing expiry in major markets. The initial patent for empagliflozin was filed in the early 2000s. For example, US Patent 7,514,447, claiming empagliflozin and related compounds, was granted in 2009 and has a term that would have expired by now in most jurisdictions, accounting for patent term extensions.
Formulation Patents: Boehringer Ingelheim has pursued patents on specific formulations to extend market exclusivity. These might cover specific particle sizes, excipient combinations, or polymorphic forms that improve stability or bioavailability. Examples could include patents claiming specific tablet compositions designed for the combination therapy.
Method of Treatment/Use Patents: Patents may cover specific uses of empagliflozin, such as its efficacy in reducing cardiovascular events or its benefits in specific patient populations. These can be crucial for protecting market share even after composition patents expire.
Polymorph Patents: Specific crystalline forms (polymorphs) of empagliflozin can be patented if they demonstrate improved properties. The patent on the most common or therapeutically advantageous polymorph is critical.

Linagliptin Patents

Composition of Matter: Similar to empagliflozin, the foundational composition of matter patents for linagliptin are also expiring or have expired. US Patent 7,435,756, claiming linagliptin, was granted in 2008 and its term, with extensions, has likely concluded or is concluding in key markets.
Formulation Patents: Boehringer Ingelheim has also secured formulation patents for linagliptin, including those relevant to its use in combination therapies.
Method of Treatment/Use Patents: Patents protecting specific therapeutic uses, such as its benefits in certain subgroups of diabetic patients or its role in combination therapy, are relevant.
Co-crystal and Salt Forms: Patents might cover specific co-crystal or salt forms of linagliptin if they offer advantages over the free base or other forms.

Metformin Hydrochloride Patents

Composition of Matter: Metformin was first synthesized in the 1920s and patented in the late 1950s. All composition of matter patents have long since expired.
Manufacturing Process Patents: While the basic synthesis is generic, novel or significantly improved manufacturing processes may be patented. These could relate to purity, yield, or environmental impact. However, these are generally less robust barriers than composition patents for market entry.
Formulation Patents (Extended Release): The most significant patent activity related to metformin has been on extended-release (ER) formulations. These patents were crucial for companies like Takeda (with Glucophage XR). For a combination product containing immediate-release metformin, these ER patents are less relevant, but if the combination product uses an ER form of metformin, then these patents would be highly significant.

Combination Product Patents

Companies often file patents specifically for fixed-dose combination products. These patents can cover:

The Combination Itself: Claiming the specific mixture of empagliflozin, linagliptin, and metformin hydrochloride, potentially within defined ratios or within a single dosage form.
Manufacturing Processes for the Combination: Novel methods for manufacturing the combined dosage form, especially if it involves challenges in compatibility or stability of the multiple APIs.
Specific Formulations: Patents on the excipients, coatings, or internal structure of a tablet or capsule containing all three APIs to ensure stability, dissolution profiles, and patient compliance.
Methods of Treatment Using the Combination: Patents claiming the efficacy of the combination for treating type 2 diabetes, particularly in patients who have not achieved adequate control on monotherapy or dual therapy.

Example Patent Considerations:

US Patent 9,095,506 (Boehringer Ingelheim): This patent, titled "Fixed combination of empagliflozin and linagliptin," claims a pharmaceutical composition containing empagliflozin and linagliptin. While it doesn't explicitly include metformin, it highlights Boehringer Ingelheim's strategy to patent combinations of their diabetes drugs.
EP 2 803 192 B1 (Boehringer Ingelheim): This European patent also covers fixed combinations of empagliflozin and linagliptin.
US Patent 9,597,172 B2 (Boehringer Ingelheim): This patent relates to specific processes for preparing empagliflozin and its salts.
US Patent 10,926,043 B2 (Boehringer Ingelheim): This patent describes pharmaceutical compositions containing empagliflozin and methods of use, potentially including combinations.

The patentability of a new fixed-dose combination product containing empagliflozin, linagliptin, and metformin hydrochloride would hinge on whether the combination offers a synergistic therapeutic effect, improved safety profile, or enhanced patient compliance that is not obvious from the individual components. Generic manufacturers aiming to enter the market with such a combination would need to navigate these patents carefully, either waiting for expiry, challenging their validity, or developing non-infringing formulations or manufacturing processes.

Key Considerations for Market Entry and Supply Chain

For companies looking to enter the market with the empagliflozin, linagliptin, and metformin hydrochloride combination, several factors are critical:

API Sourcing Strategy:
- Quality and Regulatory Compliance: Sourcing from manufacturers with robust quality management systems (cGMP compliance) and a strong regulatory track record (e.g., FDA, EMA inspected facilities) is paramount.
- Supply Chain Resilience: Diversifying API suppliers for each component can mitigate risks associated with single-source dependencies, geopolitical issues, or manufacturing disruptions.
- Cost-Effectiveness: For generic products, competitive API pricing is essential. This often points towards manufacturers in India and China, but quality assurance must remain the priority.
Intellectual Property Navigation:
- Freedom to Operate (FTO) Analysis: A thorough FTO analysis is required to ensure that the proposed product, manufacturing process, and marketing do not infringe on existing patents. This includes patents on individual APIs, formulations, manufacturing methods, and the combination product itself.
- Patent Expiry Monitoring: Closely tracking the expiry dates of key patents, especially formulation and combination patents, is vital for strategic market entry.
- Patent Litigation Risk: Understanding the patent enforcement history of the originator and potential competitors is important for assessing litigation risk.
Formulation Development:
- API Compatibility: Ensuring the chemical and physical compatibility of empagliflozin, linagliptin, and metformin hydrochloride in a single dosage form is a significant technical challenge. Excipients must be carefully selected to prevent degradation or interactions.
- Bioequivalence Studies: Generic products must demonstrate bioequivalence to the reference listed drug (RLD). This requires robust formulation development and clinical testing.
- Extended Release vs. Immediate Release: The choice of release profile for metformin (immediate vs. extended release) will significantly impact patent considerations and formulation complexity. Immediate-release metformin is more likely to face fewer patent hurdles.
Regulatory Approvals:
- Dossier Preparation: Compiling comprehensive dossiers for regulatory agencies (e.g., ANDA in the US, MAA in Europe) requires detailed information on API sourcing, manufacturing processes, quality control, and clinical data (bioequivalence).
- Inspection Readiness: Facilities involved in manufacturing the finished product and sourcing APIs must be prepared for regulatory inspections.

Key Takeaways

API Sourcing Diversification: While Boehringer Ingelheim is the originator for empagliflozin and linagliptin, a robust network of generic API manufacturers, particularly in India and China, can supply these components. Metformin HCl API has a broad supplier base globally.
Complex Patent Landscape: Empagliflozin and linagliptin are protected by a portfolio of patents covering composition, formulation, and use, though core composition patents are nearing or past expiry. Metformin HCl's composition is off-patent, but extended-release formulations have significant patent protection. Combination product patents are critical.
Strategic Market Entry: Successful market entry for a generic triple combination requires rigorous IP clearance, reliable API sourcing from cGMP-compliant manufacturers, and sophisticated formulation development to ensure API compatibility and bioequivalence.

Frequently Asked Questions

Are there any patents that currently prevent the sale of a generic empagliflozin, linagliptin, and metformin hydrochloride combination? Current patent protection depends on the specific formulation and intended market. While the core composition of matter patents for empagliflozin and linagliptin are expiring, patents on specific formulations, manufacturing processes, and the combination itself can still be in force and pose barriers. A detailed Freedom to Operate analysis is required for each specific market.
What are the typical quality requirements for API suppliers in this space? API suppliers must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality management systems, validated analytical methods, and full traceability of materials.
How does the patent status of metformin hydrochloride differ from empagliflozin and linagliptin? Metformin hydrochloride is a well-established drug with expired composition of matter patents, making its basic API widely available. Empagliflozin and linagliptin, being newer molecules, still have patent protection on their core compositions, though these are progressively expiring. The key patent activity for metformin lies in its extended-release formulations.
What are the main challenges in developing a fixed-dose combination of these three drugs? Key challenges include ensuring the chemical and physical stability of all three active pharmaceutical ingredients within a single dosage form, achieving the desired dissolution and release profiles for each API, and demonstrating bioequivalence to the respective reference products. API compatibility is a significant technical hurdle.
Can a company develop a non-infringing generic combination if existing formulation patents are still active? Yes, it is possible by developing alternative formulations that do not infringe on the claims of the existing patents. This might involve using different excipients, different polymorphic forms, alternative manufacturing processes, or by seeking patent invalidation through legal challenges.

Citations

[1] U.S. Food & Drug Administration. (n.d.). FDA approves Jardiance (empagliflozin) tablets. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-approves-jardiance-empagliflozin-tablets

[2] U.S. Food & Drug Administration. (n.d.). FDA approves Tradjenta (linagliptin) tablets. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-tradgenta-linagliptin-tablets

[3] U.S. Food & Drug Administration. (n.d.). Metformin Hydrochloride Tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/075042s034,075074s021,075075s020lbl.pdf

Suppliers and packagers for generic pharmaceutical drug: EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE